tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

OptimizeRx price target raised to $20 from $14 at Citizens JMP

Citizens JMP raised the firm’s price target on OptimizeRx (OPRX) to $20 from $14 and keeps an Outperform rating on the shares following the Q2 beat. Management expressed comfort with consensus 2026 revenue and EBITDA estimates, the analyst tells investors in a research note. The firm lifted estimates post the quarter.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1